AU2012324543B2 - Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors - Google Patents

Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors Download PDF

Info

Publication number
AU2012324543B2
AU2012324543B2 AU2012324543A AU2012324543A AU2012324543B2 AU 2012324543 B2 AU2012324543 B2 AU 2012324543B2 AU 2012324543 A AU2012324543 A AU 2012324543A AU 2012324543 A AU2012324543 A AU 2012324543A AU 2012324543 B2 AU2012324543 B2 AU 2012324543B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
brimonidine
oxymetazoline
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2012324543A
Other languages
English (en)
Other versions
AU2012324543A1 (en
Inventor
Philippe Andres
Arthur CLAPP
Warren J. Scherer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Publication of AU2012324543A1 publication Critical patent/AU2012324543A1/en
Application granted granted Critical
Publication of AU2012324543B2 publication Critical patent/AU2012324543B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AU2012324543A 2011-10-19 2012-10-12 Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors Expired - Fee Related AU2012324543B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548844P 2011-10-19 2011-10-19
US61/548,844 2011-10-19
PCT/IB2012/002500 WO2013057579A2 (en) 2011-10-19 2012-10-12 Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors

Publications (2)

Publication Number Publication Date
AU2012324543A1 AU2012324543A1 (en) 2014-05-01
AU2012324543B2 true AU2012324543B2 (en) 2017-08-10

Family

ID=47631462

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012324543A Expired - Fee Related AU2012324543B2 (en) 2011-10-19 2012-10-12 Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors

Country Status (13)

Country Link
US (1) US9744168B2 (enExample)
EP (1) EP2768502A2 (enExample)
JP (1) JP2014530846A (enExample)
KR (1) KR20140091543A (enExample)
CN (1) CN103889417A (enExample)
AU (1) AU2012324543B2 (enExample)
BR (1) BR112014009210A2 (enExample)
CA (1) CA2850273A1 (enExample)
IL (1) IL231820A0 (enExample)
MX (1) MX2014004383A (enExample)
PH (1) PH12014500783A1 (enExample)
RU (1) RU2014119879A (enExample)
WO (1) WO2013057579A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
CA2951725C (en) * 2014-06-11 2022-06-07 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
EP3522914B1 (en) * 2016-10-07 2023-03-08 Micreos Human Health B.V. Vasoconstrictive and antibacterial combination treatment for rosacea
KR102122980B1 (ko) * 2018-12-28 2020-06-18 한국프라임제약주식회사 들깨 잎 추출물을 유효성분으로 함유하는 갱년기 관련 안면홍조 완화용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
WO2009152344A2 (en) * 2008-06-11 2009-12-17 Comgenrx, Inc. Combination therapy using phosphodiesterase inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
DE2436882A1 (de) 1974-07-29 1976-02-19 Schering Ag Neue oxyphenylbutazon-derivate und ihre herstellung
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2632678C2 (de) 1976-07-16 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 6α-Fluor-12α-Halogen-Kortikoide und Verfahren zu ihrer Herstellung
NZ185295A (en) 1976-10-04 1980-04-28 Schering Ag 9-chloroprednisolone derivatives and pharmaceutical compositions
US4285967A (en) 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4908387A (en) 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
AU688380B2 (en) 1993-10-13 1998-03-12 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6117871A (en) 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (en) 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US5910312A (en) 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
AU1319200A (en) 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
SE9901295D0 (sv) 1999-04-13 1999-04-13 Jan Hedner Sätt och medel för att förebygga, behandla och diagnostisera kardiovaskulära komplikationer hos patienter med obstruktiv sömnapné
WO2001013955A1 (en) 1999-08-19 2001-03-01 Lavipharm S.A. Film forming polymers, methods of use, and devices and applications thereof
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
EP1365811A2 (en) 2000-07-14 2003-12-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
ES2424644T3 (es) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
US20090061020A1 (en) 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
CA2709199A1 (en) 2007-12-21 2009-07-02 Galderma Laboratories, Inc. Pre-surgical treatment
KR20110017365A (ko) 2008-05-30 2011-02-21 페어필드 클리니컬 트라이얼즈 엘엘씨 피부 염증 및 변색을 위한 방법 및 조성물
ES2752008T3 (es) 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
WO2009152344A2 (en) * 2008-06-11 2009-12-17 Comgenrx, Inc. Combination therapy using phosphodiesterase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VYAWAHARE, N. S. et al., 'Effect of novel synthetic evodiamine analogue on sexual behavior in male rats', Journal of Chemical Biology. 2012, vol. 5, no. 1, pages 35-42. *

Also Published As

Publication number Publication date
WO2013057579A2 (en) 2013-04-25
US9744168B2 (en) 2017-08-29
JP2014530846A (ja) 2014-11-20
US20140343067A1 (en) 2014-11-20
IL231820A0 (en) 2014-05-28
CA2850273A1 (en) 2013-04-25
KR20140091543A (ko) 2014-07-21
WO2013057579A3 (en) 2013-07-04
CN103889417A (zh) 2014-06-25
RU2014119879A (ru) 2015-11-27
AU2012324543A1 (en) 2014-05-01
MX2014004383A (es) 2014-11-12
BR112014009210A2 (pt) 2017-04-18
PH12014500783A1 (en) 2014-05-12
EP2768502A2 (en) 2014-08-27

Similar Documents

Publication Publication Date Title
EP2815748B1 (en) Compounds, formulations, and methods for treating or preventing rosacea
EP2481412B1 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
EP2501373B1 (en) Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis
US20120082625A1 (en) Combination treatment for rosacea
US20120076738A1 (en) Combination treatment for dermatological conditions
AU2014292879A1 (en) Compositions for treating skin thickening
AU2012324544B2 (en) Method for treating capillary hemangiomas
US9744168B2 (en) Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
AU2015261626A1 (en) Combination treatment for Rosacea
HK1204996B (en) Compounds, formulations, and methods for treating or preventing rosacea
HK1164126B (en) Topical composition for use in the treatment of rosacea-induced redness

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application